Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 23 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jan 2026 Last checked against Clinicaltrials.gov record.
20 Jul 2023 Results from CREAD, CREAD2 and Tauriel; assessing assess the additive prognostic value of including baseline [18F]GTP1 tau-PET with the other common predictors presented at the Alzheimer's Association International Conference 2023.
09 Nov 2022 Results from CREAD, CREAD2 and Tauriel; assessing independence in activities of daily living in People With Early Alzheimers Disease, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com